These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 578026)
1. A method for the measurement of fibrinolytic activity based on one dimensional diffusion using small glass tubes. II. With special reference to the differences between the use of plasminogen-rich fibrinogen and that of plasminogen-free fibrinogen as the substrates. Yasukouchi T; Fujine M; Kohn S; Sakurama S; Morioka T Thromb Haemost; 1977 Jun; 37(3):456-63. PubMed ID: 578026 [TBL] [Abstract][Full Text] [Related]
2. Systemic fibrinolytic activity and inhibitor levels during treatment of deep vein thrombosis with urokinase and streptokinase. Theiss W; Asbeck F; Kriessmann A; Trübestein G; Knoch K; de Swart CA; Marbert GA; van de Loo JC Thromb Haemost; 1983 Oct; 50(3):664-8. PubMed ID: 6196852 [TBL] [Abstract][Full Text] [Related]
3. [Index of fibrinolysis with new fibrin plate (author's transl)]. Hishikawa Y; Sugie I Nihon Seirigaku Zasshi; 1977; 39(1):1-11. PubMed ID: 140239 [TBL] [Abstract][Full Text] [Related]
4. In vitro comparison of fibrinolytic activity of plasminogen activators using a thrombelastographic method: in vivo evaluation of the B-chain-streptokinase complex in the dog model using pre-titered doses. Summaria L; Sandesara J; Yang G; Vagher JP; Caprini JA Thromb Haemost; 1986 Aug; 56(1):71-9. PubMed ID: 2946093 [TBL] [Abstract][Full Text] [Related]
5. On the reliability of plasminogen measurement employing the proactivator-activator converting method. Martin M Thromb Haemost; 1976 Dec; 36(3):551-65. PubMed ID: 138961 [TBL] [Abstract][Full Text] [Related]
6. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro. Matsuo O; Rijken DC; Collen D Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339 [TBL] [Abstract][Full Text] [Related]
7. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways. Munkvad S Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763 [TBL] [Abstract][Full Text] [Related]
8. [Proactivator-activator system in human plasma fibrinolysis: studies on the synthetic fibrinolytic system composed of functionally pure fibrinogen, plasminogen and proactivator, separated from human plasma]. Okamoto U Nihon Seirigaku Zasshi; 1972 Mar; 34(3):147-55. PubMed ID: 4262660 [No Abstract] [Full Text] [Related]
9. [Analytical methods of study of the system of fibrinolysis (plasminogen proactivators-activators, plasminogen-plasmin, antiplasmins, antiactivators) (literature review)]. Guseĭnov ChS; Golovastova GI; Gorelova AM; Cherenkova GM; Mikhailova ND Lab Delo; 1976; (5):276-83. PubMed ID: 62085 [No Abstract] [Full Text] [Related]
10. A new method based on one dimensional diffusion using small glass tubes for the measurement of fibrinolytic activity. I. Fibrinolytic activity of plasmin and "euglobulin + streptokinase". Yasukouchi T; Watanabe T Thromb Diath Haemorrh; 1972 Dec; 28(3):329-41. PubMed ID: 4265315 [No Abstract] [Full Text] [Related]
11. The haemostatic balance in groups of thrombosis-prone patients. With particular reference to fibrinolysis in patients with myocardial infarction. Gram J Dan Med Bull; 1990 Jun; 37(3):210-34. PubMed ID: 2192835 [TBL] [Abstract][Full Text] [Related]
12. Blood fibrinolytic system in rana tigrina. Srivastava VM; Dube B; Dube RK; Agarwal GP; Ahmad N Thromb Haemost; 1981 Jun; 45(3):252-4. PubMed ID: 7281104 [TBL] [Abstract][Full Text] [Related]
13. Fibrinolysis--a review. Kane KK Ann Clin Lab Sci; 1984; 14(6):443-9. PubMed ID: 6239587 [TBL] [Abstract][Full Text] [Related]
14. Fibrinolytic agents and their effects on the haemostatic system. Kluft C Klin Wochenschr; 1988; 66 Suppl 12():50-4. PubMed ID: 2964542 [TBL] [Abstract][Full Text] [Related]
15. Potentiation by Lys-plasminogen of clot lysis by single or two chain urokinase-type plasminogen activator or tissue-type plasminogen activator. Watahiki Y; Scully MF; Ellis V; Kakkar VV Thromb Haemost; 1989 Jun; 61(3):502-6. PubMed ID: 2508259 [TBL] [Abstract][Full Text] [Related]
16. [The progress of a fibrinolytic therapy with streptokinase, urokinase and warfarin in a thoroughbred with intermittent lameness with special reference to resonance thrombography]. Pause B; Nolte I; Geiss V; Mayer H; Lasch HG Tierarztl Prax; 1988; 16(4):377-83. PubMed ID: 3222790 [TBL] [Abstract][Full Text] [Related]
17. The activator time. A method for control of activator activity during thrombolytic therapy. Blix S Scand J Haematol; 1969; 6(4):221-6. PubMed ID: 5388562 [No Abstract] [Full Text] [Related]
18. [Ability of bovine fibrinogen to accept and retain plasminogen proactivator specific for human blood]. Belitser VA; Varetskaia TV; Tsariuk LA Ukr Biokhim Zh; 1976; 48(6):721-6. PubMed ID: 1034991 [TBL] [Abstract][Full Text] [Related]
19. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions. Wu JH; Diamond SL Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011 [TBL] [Abstract][Full Text] [Related]
20. Substrate composition and the effect of epsilon-aminocaproic acid on tissue plasminogen activator and urokinase-induced fibrinolysis. Thorsen S; Astrup T Thromb Diath Haemorrh; 1974 Dec; 32(2-3):306-24. PubMed ID: 4281113 [No Abstract] [Full Text] [Related] [Next] [New Search]